Make an Appointment

Ask a Question
Refer a Patient

1.877.CALL NJH
(877.225.5654)

National Jewish Health NamesRecipient of The CSL Behring – National Jewish Health Fellowship in Immunology

National Jewish Health (NJH)announced that Jordan Abbott, M.D., is the recipient of the CSL Behring –National Jewish Health Fellowship in Immunology for 2011. 

Funded byan unrestricted grant from CSL Behring, the fellowship program provides$85,000 per year for three years to support the education and training of youngphysicians in the Department of Pediatrics at NJH who are embarking on a careerin research and/or clinical care of people with immunodeficiency. Dr. Abbottwas selected as the result of his clinical experience, scientific knowledge,and interest in primary immunodeficiency (PI) and T-cell biology.

“Formore than a century National Jewish Health has taken responsibility for thewell-being of hundreds of patients with primary immunodeficiencies who hadnowhere else to turn. We are grateful to CSL Behring for the commitment,partnership and fellowship support,” said Erwin W. Gelfand, M.D., Chairman,Department of Pediatrics, National Jewish Health. “Training of the futuregeneration of physicians in the diagnosis and care of children and adults withprimary immunodeficiencies ensures that these patients will continue to receivethe most advanced care available to maintain their health and quality of life.”

“NationalJewish Health is one of the leading centers in the United States for research andtraining of young physicians in the field of immunology. This focus aligns withCSL Behring’s commitment to enhancing the quality of life for people with rareand serious disorders, such as PI,” said Garrett E. Bergman, M.D., SeniorDirector of Medical Affairs, North America Commercial Operations at CSLBehring. “We are pleased to partner with National Jewish Health to advanceknowledge of the underlying basic science and clinical care of patients withimmune disorders and would like to congratulate Dr. Abbott for receiving thefellowship.”

Dr. Abbottis board certified in pediatrics, receiving his residency training atChildren’s Hospital Los Angeles and his M.D. from Weill Cornell Medical College.  Prior to medical school, Dr. Abbott earned amaster's degree in biotechnology from Columbia University. 

As therecipient of the CSL Behring – National Jewish Health Fellowship in Immunologyfor 2011, Dr. Abbott will oversee the care of people with primaryimmunodeficiency in the clinic. He will direct the treatment for those managingtheir condition with intravenous immunoglobulin (IVIg) in the hospital’sinfusion center or at-home with subcutaneous immunoglobulin (SCIg). Dr. Abbottwill also interface with National Jewish Health’s Advanced DiagnosticsLaboratory and the Center for Genes Environment and Health as the hospitalproceeds to develop full genomic sequencing for mutations associated withprimary immunodeficiency. In the laboratory Dr. Abbott will study lymphocytefunction as it relates to the immune response.

About PrimaryImmunodeficiency
Primary immunodeficiency (PI) is a group of more than 150 diseases that affectthe cells, tissues and proteins of the immune system. In people with PI, theimmune system is either absent or functioning inadequately, leaving them moresusceptible to infection. For individuals with PI – many of them children –infections may not improve with treatment as expected, and may keep returning.As a result, patients may face repeated rounds of antibiotics or behospitalized for treatment. Repeated infections can lead to organ damage,which, over time, can become life-threatening. Collectively, PIs affect anestimated 10 million people worldwide, and the incidence is estimated to be 1in 10,000. For more information on PI, please visit www.treatingpi.com.

About CSL Behring

CSL Behringis a leader in the plasma protein therapeutics industry. Committed to savinglives and improving the quality of life for people with rare and seriousdiseases, the company manufactures and markets a range of plasma-derived andrecombinant therapies worldwide. CSL Behring therapies are indicated for thetreatment of coagulation disorders including hemophilia and von Willebranddisease, primary immune deficiencies, hereditary angioedema and inheritedrespiratory disease. The company’s products are also used in cardiac surgery,organ transplantation, burn treatment and to prevent hemolytic diseases innewborns. CSL Behring operates one of the world’s largest plasma collectionnetworks, CSL Plasma. CSL Behring is a subsidiary of CSLLimited (ASX: CSL),a biopharmaceutical company headquartered in Melbourne, Australia.For more information, visit www.cslbehring.com.

About National Jewish Health

NationalJewish Health is known worldwide for treatment of patients with respiratory,cardiac, immune and related disorders, and for groundbreaking medical research.Founded in 1899 as a nonprofit hospital, National Jewish remains the onlyfacility in the world dedicated exclusively to these disorders. Since 1998, U.S. News & World Report has rankedNational Jewish the #1 respiratory hospital in the nation.

NationalJewish Health is accredited by the Accreditation Council of Continuing MedicalEducation (ACCME) to provide continuing medical education for physicians.

Bookmark and Share

News Archive
Browse by Year

Search All

2014
|
2013
|
2012
|
2011

2010
|
2009
|
2008
|
2007
2006
2005
2004
2003
2002
Media Contacts

Newsroom

In the Newsroom, you can find National Jewish Health press releases, newsletters, annual reports and media contacts. Learn more.

 

Sign Up for e-Newsletters

Enter your email address to receive health tips, recent research findings and news about National Jewish Health.